Publications by authors named "A Yafasova"
Article Synopsis
- A study in Denmark investigated how thyroid dysfunction impacts heart failure (HF) outcomes in patients diagnosed with HF between 2000 and 2021.
- The research categorized patients based on thyroid function and found that those with both hypo- and hyperthyroidism had higher risks of mortality and hospitalization compared to those with normal thyroid function.
- The findings highlight the need for healthcare providers to be more aware of the risks associated with thyroid issues in patients at risk for heart failure.
Aims: Atrial fibrillation (AF) is associated with heart failure (HF). However, it is unclear if postoperative AF (POAF) following non-cardiac surgery differs from non-surgical AF in terms of the risk of HF. We compared the long-term rate of incident HF in patients developing new-onset POAF following non-cardiac surgery with patients who did not develop POAF following non-cardiac surgery and patients with non-surgical non-valvular AF (NVAF).
View Article and Find Full Text PDFBackground: Hospitalizations are a major burden for both patients and society but are potentially preventable. We examined the one-year hospitalization burden in patients undergoing transcatheter aortic valve replacement (TAVR) and compared hospitalization rates and patterns with those undergoing isolated surgical aortic valve replacement (SAVR).
Methods: Using Danish nationwide registries, we identified patients who underwent first-time TAVR and isolated SAVR (2008-2019), respectively.
Article Synopsis
- The Heart Failure Collaboratory (HFC) score evaluates pharmacotherapy for heart failure patients, and this study analyzed its impact in 1116 Danish patients with nonischemic heart failure with reduced ejection fraction (HFrEF).
- A lower modified HFC (mHFC) score was linked to increased all-cause mortality, while an mHFC score of 3-4 had better outcomes compared to scores of 1-2.
- Despite these findings, implanting cardioverter-defibrillators (ICDs) did not improve overall or cardiovascular survival rates in these patients, although it did reduce sudden cardiovascular deaths.
Article Synopsis
- Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy for patients with heart failure and left ventricular ejection fraction ≤35%, but the benefits of ICDs in patients with NYHA class III remain uncertain.
- The DANISH trial studied 1116 patients and found that those in NYHA class III/IV had higher long-term all-cause and cardiovascular mortality rates compared to those in NYHA class II.
- Despite these findings, ICD implantation did not significantly reduce all-cause or cardiovascular mortality rates in either NYHA class, indicating a limited benefit of ICD therapy for this patient population.